Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies, Inc. (NYSE: ALUR) is a medical device company focused on metabolically healthy weight loss through its Allurion Program and Allurion Smart Capsule. This news page aggregates company press releases and third-party coverage so readers can review how Allurion communicates progress on its weight-loss platform, clinical studies, regulatory milestones, and capital markets activity over time.
Company announcements frequently highlight developments related to the Allurion Smart Capsule, described as the world’s first and only swallowable, Procedureless™ gastric balloon for weight loss, and the Allurion Virtual Care Suite, which includes the Allurion Mobile App, Allurion Insights with the Iris AI Platform, and the Allurion Connected Scale. News items also cover the company’s strategic focus on metabolically healthy weight loss, including combination approaches with low-dose GLP-1 therapies and efforts to maintain or increase lean body mass in patients with overweight and obesity.
Investors and observers can use this page to follow updates on clinical evidence, such as peer-reviewed publications and case series involving the Smart Capsule, lifestyle interventions, and GLP-1 combination therapy. Allurion’s releases describe multicenter studies, case-controlled analyses, and outcomes related to weight reduction, fat mass loss, visceral fat loss, and body composition.
In addition, Allurion’s news flow includes regulatory and financial milestones, including progress in the FDA PMA process for the Allurion Smart Capsule, FDA inspections, Day-100 meetings, private placements of equity and warrants, and transactions to exchange outstanding debt for convertible preferred equity. Readers interested in ALUR news can consult this feed to see how the company reports on its operating strategy, financial results, and key risk disclosures over time.
Allurion (OTCID: ALUR) has appealed the New York Stock Exchange decision to initiate delisting proceedings under Section 802.01B, which requires a 30-day average global market capitalization of at least $15,000,000. The company plans to regain NYSE compliance or relist on the NYSE American after its FDA approval of the Allurion Gastric Balloon System on February 20, 2026.
Allurion says it will strengthen the balance sheet and fund U.S. commercialization; securities currently trade on the OTCID market while the plan is executed. No assurance of success was stated.
Allurion (OTCID: ALUR) has begun U.S. training and on-boarding of partner accounts and started manufacturing its FDA-approved product, with first shipments expected in April 2026. The launch targets patients who started then stopped GLP-1s and explores employer partnerships to broaden benefit coverage.
The company expects U.S. availability to expand through 2026 as additional partners complete training and begin offering the Allurion Program in clinical settings nationwide.
Allurion (NYSE: ALUR) received a NYSE notice initiating delisting proceedings for failure to meet Section 802.01B listing standards. The company intends to appeal and expects its common stock to continue trading on the NYSE during the review.
Allurion cited FDA approval on February 20, 2026 as the first step in a plan to regain compliance or relist, and referenced creditor negotiations, a previously announced debt-for-preferred exchange agreement, and a warrant inducement completed February 24, 2026 as part of its remediation efforts.
Allurion (NYSE: ALUR) entered a definitive agreement to effect immediate exercise of outstanding warrants for aggregate proceeds of approximately $3.0 million at a reduced exercise price of $1.15 per share. The exercise covers 2,659,565 existing warrants with closing expected on or about February 25, 2026.
In consideration, holders will receive new private-placement warrants exercisable into up to 5,319,130 shares, subject to stockholder approval and resale registration; Roth Capital Partners is financial advisor.
Allurion (NYSE: ALUR) received U.S. FDA premarket approval on February 23, 2026 for the Allurion Gastric Balloon System featuring the Allurion Smart Capsule.
The non-surgical, 15-minute orally administered device resides ~4 months in the stomach, is repeatable, and targets adults with BMI 30–40, opening access to ~80 million Americans with obesity.
Allurion (NYSE: ALUR) announced a partnership with Bionut and pharmacy partner Farmastar in Argentina to offer discounted Mounjaro (tirzepatide) for use with the Allurion Smart Capsule, expanding access to combination therapy.
Reported clinical results in 76 patients showed 23% average total body weight loss at 12 months, a 14% point increase in lean body mass share (62% to 70%), full adherence and no early discontinuations while using low doses (2.5–5.0 mg) of tirzepatide.
Allurion (NYSE: ALUR) announced preliminary, unaudited results for Q4 and full-year 2025. Management expects Q4 revenue of $3.3M–$3.7M, representing a 22%–37% quarter-over-quarter increase, and full-year revenue of approximately $15M. The company reported continued, substantial improvement in operating expenses and operating loss both quarter-over-quarter and versus the prior year. Management highlighted that a new commercial strategy implemented after a 2025 strategic pivot contributed to the quarter's revenue growth and said a potential FDA approval of the Allurion Smart Capsule is possible in 2026.
Allurion (NYSE: ALUR) reported initial results from a 76‑patient case series combining the Allurion Program (Smart Capsule + AI Virtual Care Suite) with low‑dose tirzepatide. Patients started tirzepatide at 2.5 mg, titrated to no greater than 5.0 mg, continued for 8 months, with final measures 2 months after discontinuation (total 12‑month follow‑up). After 12 months average total body weight loss was 23% and lean body mass as a percentage of body weight rose 14% (from 62% to 70%). No patients discontinued early; all remained adherent to tirzepatide. Company plans further data collection and presentation at upcoming medical meetings and aims for a prospective clinical trial.
Allurion Technologies (NYSE: ALUR) announced a peer-reviewed, case-controlled study in 1,143 patients (BMI ≥30 kg/m2) showing the Allurion Smart Capsule plus individualized lifestyle intervention produced an average 20% weight reduction at 36 weeks with greater fat mass and visceral fat loss versus lifestyle intervention alone.
The study reports nearly twice the fat reduction and preserved muscle mass, and the company cites efficacy comparable to bariatric surgery and better real-world high-dose GLP-1 outcomes at a substantially lower cost. The Smart Capsule is swallowed in an outpatient visit, is filled in the stomach, and passes naturally after four months; combined with digital remote care for behavior change.
Allurion (NYSE: ALUR) announced a strategic distribution partnership with ProSurg Medical in Brazil on November 18, 2025 to expand access to its metabolically healthy weight loss program.
The agreement leverages ProSurg's 30 years of local experience and its network across over 300 hospitals to deploy the Allurion Program alongside multidisciplinary teams (dietitians, bariatric surgeons, endoscopic specialists) and to increase combined use with GLP-1 therapy to enhance short- and long-term outcomes.